[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors",
    "summary": "Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=88b2876a8825a93f1d8073f34e8dfd0c2231d397e651fdedc128f6144ad5af48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736289920,
      "headline": "Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors",
      "id": 132316083,
      "image": "https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) reachead $146.18 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=88b2876a8825a93f1d8073f34e8dfd0c2231d397e651fdedc128f6144ad5af48"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: A Potential Beneficiary Of A Great Rotation",
    "summary": "Johnson & Johnson: A Potential Beneficiary Of A Great Rotation",
    "url": "https://finnhub.io/api/news?id=0122879c251f0c90777fb899c0ef7d939d06da037118bdb5419b4c1792092d7f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736288935,
      "headline": "Johnson & Johnson: A Potential Beneficiary Of A Great Rotation",
      "id": 132309781,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0122879c251f0c90777fb899c0ef7d939d06da037118bdb5419b4c1792092d7f"
    }
  },
  {
    "ts": null,
    "headline": "Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and Johnson & Johnson (JNJ), as well as two micro-cap stocks Rave Restaurant Group, Inc. (RAVE) and EVI Industries, Inc. (EVI).",
    "url": "https://finnhub.io/api/news?id=0faecd9b53ec09fa25004cfd9f7d89ac7a64b70ac4b94ea2e7195553c93e47ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736273760,
      "headline": "Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson",
      "id": 132306872,
      "image": "https://media.zenfs.com/en/zacks.com/54880e1e0945bec507649ee967162b69",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta Platforms, Inc. (META) and Johnson & Johnson (JNJ), as well as two micro-cap stocks Rave Restaurant Group, Inc. (RAVE) and EVI Industries, Inc. (EVI).",
      "url": "https://finnhub.io/api/news?id=0faecd9b53ec09fa25004cfd9f7d89ac7a64b70ac4b94ea2e7195553c93e47ba"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=cd1592ac05ca10d27185161dd8c69866e9dd4899738d2c61b657e8c741177d3c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736267460,
      "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "id": 132321990,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=cd1592ac05ca10d27185161dd8c69866e9dd4899738d2c61b657e8c741177d3c"
    }
  },
  {
    "ts": null,
    "headline": "J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care",
    "summary": "(Bloomberg) -- Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.Most Read from BloombergNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCan American Drivers Learn to Love Roundabouts?Dutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Don’t Shrink the BusCan States Hit the Brakes on Runaway Roadb",
    "url": "https://finnhub.io/api/news?id=bfa75fdc17fef8fb701a501bb45876c9b46329432fcee16b3e360d9610959204",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736266474,
      "headline": "J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care",
      "id": 132305545,
      "image": "https://s.yimg.com/ny/api/res/1.2/W4d30GtOnm2I4ULPSn6aaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/ee45a18e61432fe62270bf9de519f729",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.Most Read from BloombergNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCan American Drivers Learn to Love Roundabouts?Dutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Don’t Shrink the BusCan States Hit the Brakes on Runaway Roadb",
      "url": "https://finnhub.io/api/news?id=bfa75fdc17fef8fb701a501bb45876c9b46329432fcee16b3e360d9610959204"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)",
    "summary": "Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. Read more about Legend's plans in 2025.",
    "url": "https://finnhub.io/api/news?id=e5e76c8e5e25dab1746e277892198c77ad7772ae6df8e71207c2cdb948fb102f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736264454,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)",
      "id": 132305947,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2123117524/image_2123117524.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. Read more about Legend's plans in 2025.",
      "url": "https://finnhub.io/api/news?id=e5e76c8e5e25dab1746e277892198c77ad7772ae6df8e71207c2cdb948fb102f"
    }
  },
  {
    "ts": null,
    "headline": "Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'",
    "summary": "HRL leads top Aristocrats for January with a 59-year dividend streak. Discover why its high yield and low price make it a strong pick for 2025.",
    "url": "https://finnhub.io/api/news?id=127dcc70dde156a86d33a8c7c9722bc2fb8b01d0ba752307e276cbcab4031e39",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736263975,
      "headline": "Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'",
      "id": 132305890,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/166273262/image_166273262.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "HRL leads top Aristocrats for January with a 59-year dividend streak. Discover why its high yield and low price make it a strong pick for 2025.",
      "url": "https://finnhub.io/api/news?id=127dcc70dde156a86d33a8c7c9722bc2fb8b01d0ba752307e276cbcab4031e39"
    }
  },
  {
    "ts": null,
    "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regi",
    "url": "https://finnhub.io/api/news?id=7f8a16eaada016eddd8fa0fd66f821761b5fd5465df67bbe7af4753c474983a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736254800,
      "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib",
      "id": 132301184,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regi",
      "url": "https://finnhub.io/api/news?id=7f8a16eaada016eddd8fa0fd66f821761b5fd5465df67bbe7af4753c474983a6"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
    "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
    "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736249479,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
      "id": 132302431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
      "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: I'm Saying Yes To This Mess",
    "summary": "Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, despite recent challenges.",
    "url": "https://finnhub.io/api/news?id=b788dbe6578ca592456205ae2d899fe9c49493986ce4db89ef61502cc872564b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736247600,
      "headline": "Johnson & Johnson: I'm Saying Yes To This Mess",
      "id": 132301826,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, despite recent challenges.",
      "url": "https://finnhub.io/api/news?id=b788dbe6578ca592456205ae2d899fe9c49493986ce4db89ef61502cc872564b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study",
    "summary": "By Sabela Ojea Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung...",
    "url": "https://finnhub.io/api/news?id=d1cb49fceb4ee6c5ae524ad8e756b14b967107e961d8201b6db38d3af921d423",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736241195,
      "headline": "Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study",
      "id": 132300303,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung...",
      "url": "https://finnhub.io/api/news?id=d1cb49fceb4ee6c5ae524ad8e756b14b967107e961d8201b6db38d3af921d423"
    }
  },
  {
    "ts": null,
    "headline": "Subcutaneous options offer convenience for patients — and a valuable window for drugmakers",
    "summary": "New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.",
    "url": "https://finnhub.io/api/news?id=af51836dc88a0dba5ea495e67ba87d32496dff02669cb7538bf04eebd761e2ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736236800,
      "headline": "Subcutaneous options offer convenience for patients — and a valuable window for drugmakers",
      "id": 132301186,
      "image": "https://imgproxy.divecdn.com/Nxki7sJQ_sRtdf8Shf06tlxaBVIX73I_Ye0fcjlcvzw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy01MjA0OTAwMDAuanBn.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.",
      "url": "https://finnhub.io/api/news?id=af51836dc88a0dba5ea495e67ba87d32496dff02669cb7538bf04eebd761e2ee"
    }
  }
]